ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

Janjigian, Yelena Y.*; Kawazoe, Akihito; Bai, Yuxian; Xu, Jianming; Lonardi, Sara; Metges, Jean Phillipe; Yanez, Patricio; Wyrwicz, Lucjan S.; Shen, Lin; Ostapenko, Yuriy; Bilici, Mehmet; Chung, Hyun Cheol; Shitara, Kohei; Qin, Shu-Kui; Van Cutsem, Eric; Tabernero, Josep; Li, Kan; Shih, Chie-Schin; Bhagia, Pooja; Rha, Sun Young北京大学; 哈尔滨医科大学; 5
Lancet2023-12-9DOI: 10.1016/S0140-6736(23)02033-0
8被引11阅读
引用收藏
分享

摘要

Background Evidence for the efficacy of combined PD-1 and HER2 blockade with chemotherapy on progression-free and overall survival in HER2-positive gastro-oesophageal cancer is scarce. The first interim analysis of the randomised, phase 3 KEYNOTE-811 study showed a superior objective response with pembrolizumab compared with placebo when added to trastuzumab plus fluoropyrimidine and platinum-based chemotherapy. Here, we report results from protocol-specified subsequent interim analyses of KEYNOTE-811. @@@ Methods The randomised, phase 3 KEYNOTE-811 trial involved 168 medical centres in 20 countries worldwide. Patients aged 18 years or older with locally advanced or metastatic HER2-positive gastro-oesophageal junction adenocarcinoma, without previous first-line treatment, were randomly assigned (1:1) by an integrated interactive voice-response and web-response system to intravenous pembrolizumab 200 mg or placebo, both to be combined with standard chemotherapy (fluoropyrimidine and platinum-based therapy) plus trastuzumab every 3 weeks for up to 35 cycles or until disease progression, unacceptable toxic effects, or investigator or participant-initiated withdrawal. Randomisation used a block size of four and was stratified by region, PD-L1 status, and chemotherapy. Dual primary endpoints were progression-free and overall survival, analysed by intention to treat. Safety was assessed in all randomly assigned patients who received at least one dose of study treatment according to the treatment received. KEYNOTE-811 is registered with ClinicalTrials.gov (NCT03615326) and is active but not recruiting. @@@ Findings Between Oct 5, 2018, and Aug 6, 2021, 698 patients were assigned to pembrolizumab (n=350) or placebo (n=348). 564 (81%) were male and 134 (19%) were female. At the third interim analysis, 286 (82%) of 350 patients in the pembrolizumab group and 304 (88%) of 346 in the placebo group who received treatment had discontinued treatment, mostly due to disease progression. At the second interim analysis (median follow-up 28 center dot 3 months [IQR 19 center dot 4-34 center dot 3] in the pembrolizumab group and 28 center dot 5 months [20 center dot 1-34 center dot 3] in the placebo group), median progression-free survival was 10 center dot 0 months (95% CI 8 center dot 6-11 center dot 7) in the pembrolizumab group versus 8 center dot 1 months (7 center dot 0-8 center dot 5) in the placebo group (hazard ratio [HR] 0 center dot 72, 95% CI 0 center dot 60-0 center dot 87; p=0 center dot 0002). Median overall survival was 20 center dot 0 months (17 center dot 8-23 center dot 2) versus 16 center dot 9 months (15 center dot 0-19 center dot 8; HR 0 center dot 87 [0 center dot 72-1 center dot 06]; p=0 center dot 084). At the third interim analysis (median follow-up 38 center dot 4 months [IQR 29 center dot 5-44 center dot 4] in the pembrolizumab group and 38 center dot 6 months [30 center dot 2-44 center dot 4] in the placebo group), median progression-free survival was 10 center dot 0 months (8 center dot 6-12 center dot 2) versus 8 center dot 1 months (7 center dot 1-8 center dot 6; HR 0 center dot 73 [0 center dot 61-0 center dot 87]), and median overall survival was 20 center dot 0 months (17 center dot 8-22 center dot 1) versus 16 center dot 8 months (15 center dot 0-18 center dot 7; HR 0 center dot 84 [0 center dot 70-1 center dot 01]), but did not meet prespecified criteria for significance and will continue to final analysis. Grade 3 or worse treatment-related adverse events occurred in 204 (58%) of 350 patients in the pembrolizumab group versus 176 (51%) of 346 patients in the placebo group. Treatment-related adverse events that led to death occurred in four (1%) patients in the pembrolizumab group and three (1%) in the placebo group. The most common treatment -related adverse events of any grade were diarrhoea (165 [47%] in the pembrolizumab group vs 145 [42%] in the placebo group), nausea (154 [44%] vs 152 [44%]), and anaemia (109 [31%] vs 113 [33%]). Interpretation Compared with placebo, pembrolizumab significantly improved progression-free survival when combined with first-line trastuzumab and chemotherapy for metastatic HER2-positive gastro-oesophageal cancer, specifically in patients with tumours with a PD-L1 combined positive score of 1 or more. Overall survival follow-up is ongoing and will be reported at the final analysis.Funding Merck Sharp & Dohme.

学科与关键词

关键词
RESPONSE CRITERIAOPEN-LABELESOPHAGEALTHERAPYCANCER
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Lancet
发表日期
2023-12-09
卷期
第 402 卷, 第 10418 期
页码
2197-2208
DOI
10.1016/S0140-6736(23)02033-0
语言
ENGLISH
成果收录
SCIE
资助标注
Merck Sharp; Dohme

作者

  • J

    Janjigian, Yelena Y. (通讯) (第一作者)

    new

  • K

    Kawazoe, Akihito

查看全部 20 位作者收起作者
  • B

    Bai, Yuxian

    harbin med univ

  • X

    Xu, Jianming

    5 · chinese peoples liberat army gen hosp

  • L

    Lonardi, Sara

  • M

    Metges, Jean Phillipe

  • Y

    Yanez, Patricio

  • W

    Wyrwicz, Lucjan S.

  • S

    Shen, Lin

    peking univ

  • O

    Ostapenko, Yuriy

  • B

    Bilici, Mehmet

  • C

    Chung, Hyun Cheol

  • S

    Shitara, Kohei

  • Q

    Qin, Shu-Kui

    china pharmaceut univ

  • V

    Van Cutsem, Eric

  • T

    Tabernero, Josep

  • L

    Li, Kan

  • S

    Shih, Chie-Schin

  • B

    Bhagia, Pooja

  • R

    Rha, Sun Young

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417